Press release
Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing
An investigation on behalf of investors in Aptinyx Inc. (NASDAQ: APTX) shares over potential wrongdoing at Aptinyx Inc.
Investors who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm concerns whether certain Aptinyx Inc. directors breached their fiduciary duties and caused damage to the company and its shareholders.
Evanston, IL based Aptinyx Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel, proprietary, and synthetic small molecules for the treatment of brain and nervous system disorders. Aptinyx Inc. completed its initial publis offering ("IPO") on June 21, 2018, offering $16.00 per share for net proceeds of $92.2 million. However, since the IPO shares of Aptinyx Inc. (NASDAQ: APTX) declined to as low as $2.96 per share on August 26, 2019.
Those who purchased shares of Aptinyx Inc. (NASDAQ: APTX) have certain options and should contact the Shareholders Foundation.
Media Contact:
Michael Daniels
Shareholders Foundation, Inc.
3111 Camino Del Rio North
Suite 423
San Diego, CA 92108
Tel: +1-(858)-779-1554
E-Mail: mail@shareholdersfoundation.com
About Shareholders Foundation, Inc.
The Shareholders Foundation, Inc. is a professional portfolio monitoring and settlement claim filing service, and an investor advocacy group, which does research related to shareholder issues and informs investors of securities class actions, settlements, judgments, and other legal related news to the stock/financial market. Shareholders Foundation, Inc. is in contact with a large number of shareholders and offers help, support, and assistance for every shareholder. The Shareholders Foundation, Inc. is not a law firm. Referenced cases, investigations, and/or settlements are not filed/initiated/reached and/or are not related to Shareholders Foundation. The information is provided as a public service. It is not intended as legal advice and should not be relied upon.
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Aptinyx Inc. (NASDAQ: APTX) Investor Investigation over potential Wrongdoing here
News-ID: 2033814 • Views: …
More Releases from Shareholders Foundation
ALERT: Lawsuit filed for Investors who SOLD shares of Sina Corporation (formerly …
An investor, who sold shares of Sina Corporation (formerly NASDAQ: SINA) in the merger between Seina Corporation and TuSimple Holdings, Inc, filed a lawsuit over alleged violations of Federal Securities Laws by Sina Corporation (formerly NASDAQ: SINA in connection with certain allegedly false and misleading statements made.
If you sold a significant amount of shares of Sina Corporation (formerly NASDAQ: SINA) between October 13, 2020 and March 22, 2021, you have…
Lawsuit Alert: Investors who lost money with shares of Fluor Corporation (NYSE: …
An investor, who purchased shares of Fluor Corporation (NYSE: FLR), filed a lawsuit alleged violations of Federal Securities Laws by Fluor Corporation in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Fluor Corporation (NYSE: FLR) have certain options and for certain investors are short and strict deadlines running. Deadline: November 14, 2025. NYSE: FLR investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779…
Investigation announced for Long-Term Investors in shares of Sable Offshore Corp …
An investigation was announced for long-term investors in shares of Sable Offshore Corp. (NYSE: SOC) concerning potential breaches of fiduciary duties by certain directors of Sable Offshore Corp.
Investors who are current long term investors in Sable Offshore Corp. (NYSE: SOC) shares, have certain options and should contact the Shareholders Foundation at mail@shareholdersfoundation.com or call +1(858) 779 - 1554.
The investigation by a law firm for current long term investors in…
Lawsuit filed for Investors who lost money with shares of Lantheus Holdings, Inc …
An investor, who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH), filed a lawsuit over alleged violations of Federal Securities Laws by Lantheus Holdings, Inc. in connection with certain allegedly false and misleading statements.
Investors who purchased shares of Lantheus Holdings, Inc. (NASDAQ: LNTH) have certain options and for certain investors are short and strict deadlines running. Deadline: November 10, 2025. NASDAQ: LNTH investors should contact the Shareholders Foundation at mail@shareholdersfoundation.com…
More Releases for Aptinyx
Diabetic Peripheral Neuropathy Market: Trends, Demand, Forecast with CAGR of 9.7 …
According to a new report published by CoherentMI The diabetic peripheral neuropathy market is estimated to be valued at USD 4.64 Bn in 2024 and is expected to reach USD 8.89 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031.
Most recent Report, named "Diabetic Peripheral Neuropathy Market" Patterns, Offer, Size, Development, Opportunity and Forecast 2024-2031, by CoherentMI offers a complete investigation…
Diabetic Neuropathic Pain Clinical Trials | A Drug Pipeline Analysis Report 2024 …
DelveInsight's 'Diabetic Neuropathic Pain Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Neuropathic Pain therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Neuropathic Pain pipeline domain.
Download our free sample pages: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report
Leading Diabetic Neuropathic Pain companies developing novel drug candidates to…
Diabetic Neuropathic Pain Clinical Trials | A Drug Pipeline Analysis Report 2024 …
DelveInsight's 'Diabetic Neuropathic Pain Pipeline Insight 2024' report provides comprehensive global coverage of available, marketed, and pipeline Diabetic Neuropathic Pain therapies in various stages of clinical development, major pharmaceutical companies are working to advance the pipeline space and future growth potential of the Diabetic Neuropathic Pain pipeline domain.
Download our free sample pages: https://www.delveinsight.com/report-store/diabetic-neuropathic-pain-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=kpr
Key Takeaways from the Diabetic Neuropathic Pain Pipeline Report
Leading Diabetic Neuropathic Pain companies developing novel drug candidates to…
NYX-783 Market Size and Share Analysis Across 7MM and Competitive Landscape by D …
DelveInsight has released a comprehensive report titled "NYX-783 Market Forecast" offering a thorough examination and predictive insights into the NYX-783 market landscape until 2032 across the seven major markets (7MM), encompassing the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan.
The extensive report offers a thorough examination of the market potential and market share of NYX-783 in the therapeutics landscape for Post-traumatic Stress Disorder (PTSD) across…
U.S. Chemotherapy Induced Peripheral Neuropathy Treatment Market Size Set For Ex …
The Global & U.S. Chemotherapy Induced Peripheral Neuropathy Treatment market held a market value of USD 1,613.8 Million in 2020 and is forecasted to reach USD 2,373.1 Million by the year 2027. The market is anticipated to register a CAGR of 5.7% over the projected period.
Chemotherapy Induced Peripheral Neuropathy is a side effect caused by antineoplastic agent. It is one of the most frequent side effects and is a mostly…
Post-Traumatic Stress Disorder (PTSD) Market to Showcase Significant Growth Duri …
As per DelveInsight's assessment, the Post-Traumatic Stress Disorder (PTSD) Market size was found to be USD 1,740.2 million in 2021, which is expected to rise during the study period (2019-2032). Some of the key factors, such as the increase in prevalence, the launch of emerging therapies, and increased initiatives to create public awareness and knowledge of the disease, are anticipated to drive market growth. The leading pharma and biotech giants…
